Furthermore, LPAR1 inhibition with ATX inhibitors attenuated liver fibrosis, reduced the number of HCC nodules, and reversed the PLS risk gene signature [137,144]. This evidence concerns the gene LPAR1 and hepatocellular carcinoma.